Hickmann Fernanda Hermes, Cecatto Cristiane, Kleemann Daniele, Monteiro Wagner Oliveira, Castilho Roger Frigério, Amaral Alexandre Umpierrez, Wajner Moacir
Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Departamento de Patologia Clínica, Faculdade de Ciências Médicas, Universidade Estadual de Campinas, Campinas, SP, Brazil.
Biochim Biophys Acta. 2015 Jun-Jul;1847(6-7):620-8. doi: 10.1016/j.bbabio.2015.04.003. Epub 2015 Apr 11.
Patients with long-chain 3-hydroxy-acyl-CoA dehydrogenase (LCHAD) deficiency commonly present liver dysfunction whose pathogenesis is unknown. We studied the effects of long-chain 3-hydroxylated fatty acids (LCHFA) that accumulate in LCHAD deficiency on liver bioenergetics using mitochondrial preparations from young rats. We provide strong evidence that 3-hydroxytetradecanoic (3HTA) and 3-hydroxypalmitic (3HPA) acids, the monocarboxylic acids that are found at the highest tissue concentrations in this disorder, act as metabolic inhibitors and uncouplers of oxidative phosphorylation. These conclusions are based on the findings that these fatty acids decreased ADP-stimulated (state 3) and uncoupled respiration, mitochondrial membrane potential and NAD(P)H content, and, in contrast, increased resting (state 4) respiration. We also verified that 3HTA and 3HPA markedly reduced Ca2+ retention capacity and induced swelling in Ca2+-loaded mitochondria. These effects were mediated by mitochondrial permeability transition (MPT) induction since they were totally prevented by the classical MPT inhibitors cyclosporin A and ADP, as well as by ruthenium red, a Ca2+ uptake blocker. Taken together, our data demonstrate that the major monocarboxylic LCHFA accumulating in LCHAD deficiency disrupt energy mitochondrial homeostasis in the liver. It is proposed that this pathomechanism may explain at least in part the hepatic alterations characteristic of the affected patients.
长链3-羟基酰基辅酶A脱氢酶(LCHAD)缺乏症患者通常存在肝功能障碍,但其发病机制尚不清楚。我们使用幼年大鼠的线粒体提取物,研究了LCHAD缺乏症中蓄积的长链3-羟基脂肪酸(LCHFA)对肝脏生物能量学的影响。我们提供了有力证据,表明在该疾病中组织浓度最高的单羧酸3-羟基十四烷酸(3HTA)和3-羟基棕榈酸(3HPA)可作为氧化磷酸化的代谢抑制剂和解偶联剂。这些结论基于以下发现:这些脂肪酸降低了ADP刺激的(状态3)和解偶联呼吸、线粒体膜电位和NAD(P)H含量,相反,增加了静息(状态4)呼吸。我们还证实,3HTA和3HPA显著降低了Ca2+保留能力,并诱导了Ca2+负载的线粒体肿胀。这些效应是由线粒体通透性转换(MPT)诱导介导的,因为经典的MPT抑制剂环孢素A和ADP以及Ca2+摄取阻滞剂钌红完全阻止了这些效应。综上所述,我们的数据表明,LCHAD缺乏症中蓄积的主要单羧酸LCHFA破坏了肝脏线粒体的能量稳态。有人提出,这种发病机制可能至少部分解释了受影响患者的肝脏改变特征。